CHARTER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 CHECH的总体目标是在现代抗逆转录病毒(ARV)治疗方法的背景下，采用经过验证的可靠评估方法来确定艾滋病毒感染的神经生物学和神经行为并发症的流行率和特征。这些措施包括使用联合抗逆转录病毒疗法(“高效抗逆转录病毒疗法”或“HAART”)，以及新出现的治疗方法，如程序性中断治疗、免疫疗法的使用以及特定神经保护剂的可能可获得性。此外，将对选定的“感兴趣”群体进行纵向跟踪，以深入了解作为治疗的病毒学和免疫学反应的神经生物学和神经行为结果、可用于渗透到中枢神经系统(CNS)的药物的可用性以及各种抗逆转录病毒疗法的过去和现在的经验。为了继续推进我们对神经发病机制和早期发现的理解，以及开发可能为未来对这些问题的研究提供信息的信息，Charge建议使用特定的方法纵向检查受试者的亚组，这些方法可以揭示选定病例中的代谢/血脂紊乱(以及这些影响的CNS/PNS影响)、结构和功能脑成像、病毒基因组研究和群体药代动力学研究。 为了实现这些目标和实现宪章议定书中列举的科学目标，我们的网站将准备开始积累预计每个网站每年67名HIV+患者，为期四年的横断面研究(整个6个网站研究总计1,600人)。每年，每个站点将在纵向发病机制研究中选择大约25个病例进行长期随访(总共6个站点研究n=600)。这些病例的选择将基于对纵向数据的具体需求，以回答宪章议定书中描述的HAART时代关于艾滋病毒-CNS疾病的某些关键问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overarching aim of CHARTER is to employ validated reliable assessment methodologies to ascertain the prevalence and characteristics of neurobiological and neurobehavioral complications of HIV infection in the context of modern anti-retroviral (ARV) treatment approaches. These include the use of combination ARV ("highly actively antiretroviral treatment" or "HAART"), as well as the emerging treatment methodologies such as programmed interruption of treatment, the use of immunotherapies, and the possible availability of specific neuroprotective agents. In addition, selected groups "of interest" will be followed longitudinaly in order to gain insights into neurobiological and neurobehavioral outcomes as a function of virologic and immunologic response to treatment, the availability of drugs to penetate into the central nervous system (CNS), and past and present experience with various antiretroviral regimens. To continue to advance our understanding into mechanisms and early detection of neuropathogenesis, as well as to develop information that may inform future research into these questions, CHARTER proposes to examine longitudinally subgroups of subjects with specific methodologies that can shed light on metabolic/lipid disturbances in selected cases (and the CNS/PNS impacts of these), structural and functional brain imaging, viral genomics studies, and studies of population pharmacokinetics. To accomplish these goals and to address the scientific aims enumerated in the CHARTER protocol, our site will be prepared to commence accrual of an anticipated 67 HIV+ individuals annually per site per year for four years into the Cross-Sectional Study (total for entire 6 site study n=1,600). Each year, each site will select approximately 25 cases for long-term follow-up in the Longitudinal Pathogenesis Study (total for 6 site study n=600). These cases will be selected on the basis of there being a specific need for longitudinal data to answer certain critical questions about HIV CNS disease in the era of HAART as described in the CHARTER protocol.